Home
Live Updates
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibbs Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma : comparemela.com
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
Recommendation based on results from CheckMate -901, the first Phase 3 trial with an immunotherapy-chemotherapy combination to demonstrate a survival benefit versus standard-of-care chemotherapy...
Related Keywords
United States ,
Japan ,
Taiwan ,
South Korea ,
China ,
Bristol Myers Squibb ,
Dana Walker ,
European Medicines Agency ,
Company Opdivo ,
Twitter ,
Instagram ,
Global Program ,
Youtube ,
Exchange Commission ,
European Union ,
European Commission ,
Committee For Medicinal Products Human Use ,
Ono Pharmaceutical Co ,
Linkedin ,
Drug Administration ,
European Society Of Medical Oncology ,
Facebook ,
Medicinal Products ,
Human Use ,
Global Program Lead ,
Genitourinary Cancers ,
Bristol Myers ,
European Society ,
Medical Oncology ,
Blinded Independent Central Review ,
Hazard Ratio ,
Confidence Interval ,
Important Safety Information ,
Myers Squibb ,
Better Future ,
Fatal Immune Mediated Adverse ,
Full Prescribing Information ,
Allogeneic Hematopoietic Stem Cell ,
Multiple Myeloma ,
Thalidomide Analogue ,
Prescribing Information ,
Ono Pharmaceutical ,
Private Securities Litigation Reform Act ,
Annual Report ,
Quarterly Reports ,
Current Reports ,
Markets ,
comparemela.com © 2020. All Rights Reserved.